AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22540248 — intervention group
Group type: COMPARATOR
Intervention: Intermittent catheterization
Number of subjects: 139
Study 20634666 — intervention group
Group type: EXPERIMENTAL
Intervention: Full construct vaccine (recombinant fowlpox virus carrying genes for HIV Gag-Pol and IFN-gamma)
Number of subjects: 23
Study 20634666 — intervention group
Group type: COMPARATOR
Intervention: Partial construct (without IFN-gamma)
Number of subjects: 23
Study 20634666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 20634666 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with IgG2 anti-p24 and 'high-affinity' polymorphism of FcgammaRIIa
Number of subjects: 23
Study 18811597 — intervention group
Group type: EXPERIMENTAL
Intervention: WMTA Angelus
Number of subjects: 70
Study 18811597 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA Bio
Number of subjects: 70
Study 18811597 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro‐Root MTA
Number of subjects: 70
Study 18811597 — intervention group
Group type: EXPERIMENTAL
Intervention: Portland cement
Number of subjects: 70
Study 18811597 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 teeth)
Number of subjects: 70
Study 16164709 — intervention group
Group type: EXPERIMENTAL
Intervention: C. indicum extract-based cream (n = 125)
Number of subjects: 246
Study 16164709 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 121)
Number of subjects: 246
Study 12911418 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg/day
Number of subjects: 294
Study 12911418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study 10731407 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncompressed images
Number of subjects: 21
Study 10731407 — intervention group
Group type: EXPERIMENTAL
Intervention: Compressed images at CR 6:1
Number of subjects: 21
Study 10731407 — intervention group
Group type: EXPERIMENTAL
Intervention: Compressed images at CR 10:1
Number of subjects: 21
Study 10731407 — intervention group
Group type: EXPERIMENTAL
Intervention: Compressed images at CR 16:1
Number of subjects: 21
Study 8666350 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 1531215 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional radiotherapy plus etanidazole (2 g/m2 i.v. 30 to 60 min before radiotherapy each Monday, Wednesday, and Friday to 34 g/m2 in 17 doses)
Number of subjects: 33
Study 1531215 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 33
Study 2580144 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg twice daily)
Number of subjects: 2
Study 2580144 — intervention group
Group type: COMPARATOR
Intervention: Control state (no ketanserin)
Number of subjects: 2
Study 30321655 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily GSP301 (665 μg olopatadine and 25 μg mometasone)
Number of subjects: 180
Study 30321655 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily GSP301 (665 μg olopatadine and 50 μg mometasone)
Number of subjects: 180
Study 30321655 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice-daily)
Number of subjects: 180
Study 30321655 — intervention group
Group type: EXPERIMENTAL
Intervention: AzeFlu (137 μg azelastine and 50 μg fluticasone, twice-daily)
Number of subjects: 180
Study 30321655 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine (twice-daily)
Number of subjects: 180
Study 29957728 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol blend (PPB) supplementation
Number of subjects: 38
Study 29957728 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 38
Study 29957728 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 38
Study 27169789 — intervention group
Group type: EXPERIMENTAL
Intervention: BPT + DIS
Number of subjects: 110
Study 27169789 — intervention group
Group type: EXPERIMENTAL
Intervention: BPT + DIS + AM
Number of subjects: 110
Study 27169789 — intervention group
Group type: COMPARATOR
Intervention: BPT + S
Number of subjects: 110
Study 27169789 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 110
Study 27169789 — intervention group
Group type: EXPERIMENTAL
Intervention: AM
Number of subjects: 110
Study 25041265 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative perihepatic drain (IPD)
Number of subjects: 199
Study 25041265 — intervention group
Group type: COMPARATOR
Intervention: No drains (control group)
Number of subjects: 199
Study 23200625 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 200/25 μg or 100/12.5 μg once daily for 7 days in patients with hepatic impairment
Number of subjects: 44
Study 23200625 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 200/25 μg or 100/12.5 μg once daily for 7 days in patients with moderate hepatic impairment
Number of subjects: 44
Study 23200625 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate/vilanterol (FF/VI) 200/25 μg or 100/12.5 μg once daily for 7 days in patients with renal and hepatic impairment
Number of subjects: 44
Study 20039787 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (n=134)
Number of subjects: 267
Study 20039787 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care (n=133)
Number of subjects: 267
Study 20039787 — intervention group
Group type: COMPARATOR
Intervention: General population (NOWAC study)
Number of subjects: 267
Study 18806065 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated bolus doses of 5 mL every hour of 0.125% levobupivacaine for 24 h
Number of subjects: 44
Study 18806065 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of 0.125% levobupivacaine with an infusion rate of 5 mL/h for 24 h
Number of subjects: 44
Study 16106493 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy (D2)
Number of subjects: 523
Study 16106493 — intervention group
Group type: COMPARATOR
Intervention: Superextended lymphadenectomy (D3)
Number of subjects: 523
Study 16106493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatectomy
Number of subjects: 523
Study 16106493 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged operating time
Number of subjects: 523
Study 16106493 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index ≥ 25 kg/m2
Number of subjects: 523
Study 16106493 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > 65 years
Number of subjects: 523
Study 12394892 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical care with physical therapy
Number of subjects: 681
Study 12394892 — intervention group
Group type: COMPARATOR
Intervention: Chiropractic care
Number of subjects: 681
Study 12394892 — intervention group
Group type: COMPARATOR
Intervention: Medical care alone
Number of subjects: 681
Study 12394892 — intervention group
Group type: COMPARATOR
Intervention: Medical care without physical therapy
Number of subjects: 681
Study 10413128 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.25%)
Number of subjects: 50
Study 10413128 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 50
Study 7769290 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg/day
Number of subjects: 300
Study 7769290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 2255266 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone (NET)
Number of subjects: 80
Study 2255266 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural micronized progesterone (NMP)
Number of subjects: 80
Study 376131 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 mg 3 times daily)
Number of subjects: 101
Study 376131 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (10 mg 3 times daily) plus Medroxyprogesterone acetate (100 mg once daily)
Number of subjects: 101
Study 31985125 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time geriatric assessment report provided to clinicians
Number of subjects: 135
Study 31985125 — intervention group
Group type: COMPARATOR
Intervention: No geriatric assessment report provided to clinicians (Control)
Number of subjects: 135
Study 31679821 — intervention group
Group type: EXPERIMENTAL
Intervention: OM3-PL/FFA 1 g/d
Number of subjects: 42
Study 31679821 — intervention group
Group type: EXPERIMENTAL
Intervention: OM3-PL/FFA 2 g/d
Number of subjects: 42
Study 31679821 — intervention group
Group type: EXPERIMENTAL
Intervention: OM3-PL/FFA 4 g/d
Number of subjects: 42
Study 31679821 — intervention group
Group type: EXPERIMENTAL
Intervention: OM3-PL/FFA after HF breakfast on day 15
Number of subjects: 42
Study 31679821 — intervention group
Group type: EXPERIMENTAL
Intervention: OM3-PL/FFA (all doses)
Number of subjects: 42
Study 28733301 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D navigation template guided surgery
Number of subjects: 0
Study 25611190 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal lavage
Number of subjects: 193
Study 25611190 — intervention group
Group type: COMPARATOR
Intervention: Non-lavage
Number of subjects: 193
Study 23529917 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 0
Study 23529917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21367953 — intervention group
Group type: EXPERIMENTAL
Intervention: Refeeding intervention after a median of 95 days (IQR 88-125 days)
Number of subjects: 7
Study 21367953 — intervention group
Group type: EXPERIMENTAL
Intervention: Refeeding intervention
Number of subjects: 7
Study 21367953 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 7
Study 19232936 — intervention group
Group type: EXPERIMENTAL
Intervention: two mg of butorphanol in 10 mL of 0.125% bupivacaine (Group 2)
Number of subjects: 60
Study 19232936 — intervention group
Group type: EXPERIMENTAL
Intervention: two mg of butorphanol in 10 mL of 0.25% bupivacaine (Group 3)
Number of subjects: 60
Study 19232936 — intervention group
Group type: EXPERIMENTAL
Intervention: two mg of butorphanol in 10 mL of normal saline (Group 1)
Number of subjects: 60
Study 17761370 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine
Number of subjects: 23
Study 15095233 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine, 10 mg q.d. for 6 weeks
Number of subjects: 200
Study 15095233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 15095233 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 200
Study 11546717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 15 mg and preservative-free morphine 200 microg with fentanyl 0.02 mg
Number of subjects: 44
Study 11546717 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal bupivacaine 15 mg and preservative-free morphine 200 microg without fentanyl (Control group)
Number of subjects: 44
Study 9511041 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline therapy for 4 months
Number of subjects: 34
Study 9511041 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 months
Number of subjects: 34
Study 8141214 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 105
Study 8141214 — intervention group
Group type: COMPARATOR
Intervention: Standard obstetric care without amnioinfusion
Number of subjects: 105
Study 3375787 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral, attenuated live Salmonella typhi Ty 21a vaccine (Vivotif)
Number of subjects: 44000
Study 3375787 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized vaccine reconstituted in a buffer solution
Number of subjects: 44000
Study 3375787 — intervention group
Group type: COMPARATOR
Intervention: Initially marketed formulation (2 bicarbonate capsules + vaccine capsule)
Number of subjects: 44000
Study 1115014 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4 g/kg body weight protein intake
Number of subjects: 2
Study 1115014 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.8 g/kg body weight protein intake
Number of subjects: 2
Study 1115014 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving adequate protein intake
Number of subjects: 2
Study 1115014 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diets
Number of subjects: 2
Study 1115014 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g of protein/day
Number of subjects: 2
Study 31722153 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary surgical cytoreduction followed by platinum-based chemotherapy
Number of subjects: 485
Study 31722153 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 485
Study 28544495 — intervention group
Group type: EXPERIMENTAL
Intervention: Interspinous fastener (ISF)
Number of subjects: 46
Study 28544495 — intervention group
Group type: COMPARATOR
Intervention: Pedicle screws
Number of subjects: 46
Study 26775456 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 80
Study 26775456 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine
Number of subjects: 80
Study 23233321 — intervention group
Group type: EXPERIMENTAL
Intervention: ALX‐0081
Number of subjects: 55
Study 23233321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 21245879 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose (0.083% w/v)
Number of subjects: 8
Study 21245879 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified sham-feeding of sucralose (0.083% w/v)
Number of subjects: 8
Study 21245879 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrin (50% w/v maltodextrin + 0.083% sucralose)
Number of subjects: 8
Study 21245879 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 8
Study 18285619 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg lisdexamfetamine capsule
Number of subjects: 18
Study 18285619 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine in solution
Number of subjects: 18
Study 18285619 — intervention group
Group type: COMPARATOR
Intervention: 70 mg lisdexamfetamine capsule with high-fat meal
Number of subjects: 18
Study 16540958 — intervention group
Group type: COMPARATOR
Intervention: Propofol by continuous infusion
Number of subjects: 0
Study 16540958 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam by intermittent bolus administration
Number of subjects: 0
Study 12670567 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg
Number of subjects: 487
Study 12670567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study 11052839 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin
Number of subjects: 2175
Study 11052839 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 2175
Study 9175220 — intervention group
Group type: EXPERIMENTAL
Intervention: IABP treatment for 2 hours prior to CPB
Number of subjects: 33
Study 9175220 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative IABP)
Number of subjects: 33
Study 1531823 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 120
Study 1531823 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 120
Study 1531823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 3927931 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (Acupan)
Number of subjects: 90
Study 3927931 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine
Number of subjects: 90
Study 3927931 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 90
Study 31221280 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal sodium diet (NS: 7 g/day of dietary sodium chloride)
Number of subjects: 44
Study 31221280 — intervention group
Group type: COMPARATOR
Intervention: Low sodium diet (LS: 3 g/day of dietary sodium chloride)
Number of subjects: 44
Study 29343128 — intervention group
Group type: EXPERIMENTAL
Intervention: brexpiprazole 2-3 mg/day
Number of subjects: 0
Study 29343128 — intervention group
Group type: COMPARATOR
Intervention: quetiapine XR 150-300 mg/day
Number of subjects: 0
Study 29343128 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 27082942 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week ligation interval
Number of subjects: 90
Study 27082942 — intervention group
Group type: COMPARATOR
Intervention: 2-week ligation interval
Number of subjects: 90
Study 24586717 — intervention group
Group type: EXPERIMENTAL
Intervention: First dose of MR vaccine administered at 8 months and second dose of MMR vaccine administered at 18-24 months
Number of subjects: 1015
Study 21719234 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting
Number of subjects: 120
Study 21719234 — intervention group
Group type: COMPARATOR
Intervention: Standing
Number of subjects: 120
Study 20217197 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher threat warnings from a medical source
Number of subjects: 258
Study 20217197 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher threat warnings from a provider source
Number of subjects: 258
Study 20217197 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no threat warning)
Number of subjects: 258
Study 20217197 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher threat warnings
Number of subjects: 258
Study 20217197 — intervention group
Group type: EXPERIMENTAL
Intervention: Depth of Information Processing
Number of subjects: 258
Study 17686441 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab added to carboplatin/paclitaxel
Number of subjects: 0
Study 17686441 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab added to cisplatin/vinorelbine
Number of subjects: 0
Study 17686441 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib monotherapy
Number of subjects: 0
Study 17686441 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib versus chemotherapy
Number of subjects: 0
Study 17686441 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib monotherapy in recurrent disease
Number of subjects: 0
Study 17686441 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib/bevacizumab versus bevacizumab/chemotherapy versus chemotherapy alone
Number of subjects: 0
Study 15861904 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Intensive Follow-Up Program (SIFUP), n=129
Number of subjects: 237
Study 15861904 — intervention group
Group type: COMPARATOR
Intervention: General Cardiology Outpatient Department (COD), n=108
Number of subjects: 237
Study 12095487 — intervention group
Group type: EXPERIMENTAL
Intervention: CC + recombinant FSH + recombinant LH (group A)
Number of subjects: 294
Study 12095487 — intervention group
Group type: COMPARATOR
Intervention: long GnRH-a suppression + recombinant FSH (group B)
Number of subjects: 294
Study 10484950 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5.0 mg at bedtime
Number of subjects: 257
Study 10484950 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 0.5 mg at bedtime
Number of subjects: 257
Study 10484950 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 0.5 mg taken on a shifting schedule
Number of subjects: 257
Study 10484950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 8733853 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical flurbiprofen 0.03% solution applied every 15 minutes for 60 to 75 minutes before surgery
Number of subjects: 236
Study 8733853 — intervention group
Group type: COMPARATOR
Intervention: Topical indomethacin 1% suspension applied every 15 minutes for 60 to 75 minutes before surgery
Number of subjects: 236
Study 1808052 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 38
Study 1808052 — intervention group
Group type: COMPARATOR
Intervention: Control (no ranitidine)
Number of subjects: 38
Study 7075644 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg 3 times daily)
Number of subjects: 26
Study 7075644 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine + Metoprolol
Number of subjects: 26
Study 7075644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 30995295 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment with 2,850 kcal/kg and 16% CP
Number of subjects: 240
Study 30995295 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment with 2,950 kcal/kg and 16.5% CP
Number of subjects: 240
Study 30995295 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment with 3,050 kcal/kg and 17.0% CP
Number of subjects: 240
Study 30995295 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment with 3,150 kcal/kg and 17.5% CP
Number of subjects: 240
Study 30995295 — intervention group
Group type: EXPERIMENTAL
Intervention: Lard and palm oil diets
Number of subjects: 240
Study 30995295 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil diet
Number of subjects: 240
Study 30995295 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm oil diet
Number of subjects: 240
Study 30995295 — intervention group
Group type: EXPERIMENTAL
Intervention: Lard diet
Number of subjects: 240
Study 30995295 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of emulsifier
Number of subjects: 240
Study 30515416 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine (group D) - continuous intravenous infusion of dexmedetomidine 1 μg/kg over 15 minutes before endoscopy
Number of subjects: 88
Study 30515416 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (group P) - intravenously administered 2 mg/kg
Number of subjects: 88
Study 26815196 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 59
Study 26815196 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 59
Study 26815196 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole
Number of subjects: 59
Study 26815196 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 59
Study 25132426 — intervention group
Group type: EXPERIMENTAL
Intervention: Head Start (HS) program
Number of subjects: 2449
Study 22492899 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred drug lists
Number of subjects: 0
Study 22492899 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum allowable cost policy
Number of subjects: 0
Study 22492899 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint and multistate purchasing arrangements
Number of subjects: 0
Study 22492899 — intervention group
Group type: COMPARATOR
Intervention: Overall effect of all policies
Number of subjects: 0